Home › Gastrointestinal Cancers › Tennessee
Gastrointestinal Cancers clinical trials in Tennessee
13 studies for Gastrointestinal Cancers are looking for participants at sites in Tennessee.
Cities in Tennessee
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07544589A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Knoxville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07218926A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06760819Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07283939Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Henry-Joyce Cancer Clinic, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07222800DESTINY-PANTUMOUR04
- Research Site, Nashville
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06445062Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT06040541A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Baptist Memorial Hospital Baptist Cancer Center, Memphis
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Tennessee Oncology, Chattanooga
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT05379985A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT07020221From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.